The Taskforce acknowledges the publication of a joint media release from the REMAP-CAP, ACTIV-4 and ATTACC trial teams on December 22nd, 2020.
The investigators have reported that among critically ill COVID-19 patients requiring intensive care unit (ICU) support, therapeutic anticoagulation drugs did not improve outcome measured using a composite of in-hospital mortality and duration of organ failure support in hospital survivors, that a potential for harm in this sub-group could not be excluded, and that all trial sites have paused enrolment of this group of patients.
The Taskforce awaits publication of the relevant trial results and if deemed significant to the Australian setting will convene an emergency meeting of the Critical Care Panel to consider changes to Taskforce recommendations